SeaStar Medical Holding Co. (NASDAQ:ICU) Sees Significant Increase in Short Interest

SeaStar Medical Holding Co. (NASDAQ:ICU) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 357,600 shares, an increase of 18.8% from the February 13th total of 300,900 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average daily volume of 421,900 shares, the short-interest ratio is presently 0.8 days.

SeaStar Medical Price Performance

ICU stock traded up $0.01 during mid-day trading on Tuesday, hitting $2.18. 106,467 shares of the stock were exchanged, compared to its average volume of 246,017. The business has a fifty day moving average price of $1.83 and a 200 day moving average price of $2.75. SeaStar Medical has a 12 month low of $1.50 and a 12 month high of $22.00. The stock has a market capitalization of $14.11 million, a price-to-earnings ratio of -0.19 and a beta of -0.97.

Institutional Investors Weigh In On SeaStar Medical

A hedge fund recently raised its stake in SeaStar Medical stock. Geode Capital Management LLC increased its stake in SeaStar Medical Holding Co. (NASDAQ:ICU) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,430 shares of the company’s stock after acquiring an additional 5,618 shares during the period. Geode Capital Management LLC owned about 1.02% of SeaStar Medical worth $88,000 as of its most recent SEC filing. Institutional investors own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.